Discrimination of the Effects of Doxorubicin on Two Different Breast Cancer Cell Lines on Account of Multidrug Resistance and Apoptosis

Öncül, Selin; Ercan, Ayşe

doi:10.4172/pharmaceutical-sciences.1000268

Cited by 11 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results suggested that cell cycle arrest is predominantly induced at the G2/M checkpoint in MDA-MB-231 cells treated with doxorubicin or gefitinib for 24 h, although the effect was more evident in gefitinib. Similar results were also reported in previous studies, where MDA-MB-231 cells accumulated largely in the G2/M phase due to reduced expression of CDK1, CDK2, and cyclin-B1 (Oncul and Ercan, 2017;Wei et al, 2020). A significant increase in a sub-G1 fraction was observed in the cells treated with gefitinib for 24 h compared with control (22.8 and 2%, respectively), and maximum at 48 h (55.1 and 1.7%, respectively).…”

Section: Discussionsupporting

confidence: 90%

Chalcone-3 Inhibits the Proliferation of Human Breast Cancer MDA-MB-231 Cell Line

Padauleng

Mustofa

Wahyuningsih

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: Chalcone-3 has been shown to be cytotoxic and selective against luminal subtype breast cancer cell lines, which are suspected to occur through the mechanism of epidermal growth factor receptors (EGFR) inhibition. However, the cytotoxic effect has never been tested on cell strains from patients with triple negative breast cancer (TNBC), where EGFR expression is known to increase. This study aimed to identify the role of chalcone-3 in one of the downstream targets of EGFR as an antiproliferative agent. Methods: Chalcone-3 was examined for its effect on proliferation in human breast cancer MDA-MB-231 cell lines. The percentage of proliferation inhibition was analyzed using methyl-thiazol tetrazolium assay. Flow cytometry was used to analyze the population of cell cycle distribution and the expression of cyclin-D1 and pEGFR. Results: Chalcone-3 inhibited the proliferation of MDA-MB-231 cells in a dose and time-dependent manner with an IC 50 value of 17.98±6.36 µg/mL by inducing cell cycle arrest at the G2/M phase. Flow cytometry assays showed that chalcone-3 significantly reduced the expression of pEGFR and cyclin-D1, contributing to cell cycle arrest. Conclusion: Chalcone-3 might have potential as an anti-proliferative drug to treat TNBC.

show abstract

Section: Discussionsupporting

confidence: 90%

Chalcone-3 Inhibits the Proliferation of Human Breast Cancer MDA-MB-231 Cell Line

Padauleng

Mustofa

Wahyuningsih

et al. 2023

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Both MDA-MB-231 [79] and MCF-7 [78] cell lines have shown the ability to gain resistance to doxorubicin. Nevertheless, the opposite can happen and some studies have shown a lower IC 50 for DOX in MDA-MB-231 than in MCF-7 cells [80,81]. Different rates of nanoparticles uptake, depending on cell type, may also be at play to explain this.…”

Section: Antiproliferative and Cytotoxicity In Vitro Evaluationmentioning

confidence: 99%

“…Our results thus show the potential of the hybrid nanoparticles as a novel anticancer drug delivery system. lower IC50 for DOX in MDA-MB-231 than in MCF-7 cells [80,81]. Different rates of nanoparticles uptake, depending on cell type, may also be at play to explain this.…”

Section: Antiproliferative and Cytotoxicity In Vitro Evaluationmentioning

confidence: 99%

Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Doxorubicin is one of the most widely used anti-cancer drugs, but side effects and selectivity problems create a demand for alternative drug delivery systems. Herein we describe a hybrid magnetic nanomaterial as a pH-dependent doxorubicin release carrier. This nanocarrier comprises magnetic iron oxide cores with a diameter of 10 nm, enveloped in a hybrid material made of siliceous shells and ĸ-carrageenan. The hybrid shells possess high drug loading capacity and a favorable drug release profile, while the iron oxide cores allows easy manipulation via an external magnetic field. The pH responsiveness was assessed in phosphate buffers at pH levels equivalent to those of blood (pH 7.4) and tumor microenvironment (pH 4.2 and 5). The nanoparticles have a loading capacity of up to 12.3 wt.% and a release profile of 80% in 5 h at acidic pH versus 25% at blood pH. In vitro drug delivery tests on human breast cancer and non-cancer cellular cultures have shown that, compared to the free drug, the loaded nanocarriers have comparable antiproliferative effect but a less intense cytotoxic effect, especially in the non-cancer cell line. The results show a clear potential for these new hybrid nanomaterials as alternative drug carriers for doxorubicin.

show abstract

“…The cycle arrest was evident in both G0/G1 and G2/M phases in MCF-7 cells, while it was most prominent in G2/M phase in MDA-MB-231 cells. Oncul and co-workers obtained similar results when Dox was used in MCF-7 and MDA-MB-231 cells to study multidrug resistance and apoptosis [ 38 ].…”

Section: Resultsmentioning

confidence: 80%

Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer

Prajapati

García-Garrido

Somoza

2021

Cancers

View full text Add to dashboard Cite

Albumin-based nanoparticles are an emerging platform for the delivery of various chemotherapeutics because of their biocompatibility, safety, and ease of surface modification for specific targeting. The most widely used method for the preparation of albumin nanoparticles is by desolvation process using glutaraldehyde (GLU) as a cross-linker. However, limitations of GLU like toxicity and interaction with drugs force the need for alternative cross-linkers. In the present study, several cross-linking systems were evaluated for the preparation of Bovine Serum Albumin (BSA) nanoparticles (ABNs) encapsulating Doxorubicin (Dox). Based on the results obtained from morphological characterization, in vitro release, and therapeutic efficacy in cells, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP)-modified ABNs (ABN-SPDP) was chosen. Since ABN-SPDP are formed with disulfide linkage, the drug release is facilitated under a highly reducing environment present in the tumor sites. The cytotoxicity studies of those ABN-SPDP were performed in three different breast cell lines, highlighting the mechanism of cell death. The Dox-encapsulated ABN-SPDP showed toxicity in both the breast cancer cells (MCF-7 and MDA-MB-231), but, remarkably, a negligible effect was observed in non-tumoral MCF-10A cells. In addition to the hydrophilic Dox, this system could be used as a carrier for hydrophobic drugs like SN38. The system could be employed for the preparation of nanoparticles based on human serum albumin (HSA), which further enhances the feasibility of this system for clinical use. Hence, the albumin nanoparticles developed herein present an excellent potential for delivering various drugs in cancer therapy.

show abstract

Discrimination of the Effects of Doxorubicin on Two Different Breast Cancer Cell Lines on Account of Multidrug Resistance and Apoptosis

Cited by 11 publications

References 24 publications

Chalcone-3 Inhibits the Proliferation of Human Breast Cancer MDA-MB-231 Cell Line

Chalcone-3 Inhibits the Proliferation of Human Breast Cancer MDA-MB-231 Cell Line

Magnetic Driven Nanocarriers for pH-Responsive Doxorubicin Release in Cancer Therapy

Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer

Contact Info

Product

Resources

About